Drugs / Galvokimig
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06315335 | Jul 2024 → Jan 2025 | — | UCB Biopharma SRL | Completed | No outcome recorded |
| Phase 1/21 trial · 1 met primary | ||||||
| Phase 1/2 | NCT04643457 | Nov 2020 → Apr 2024 | atopic eczema | UCB Biopharma SRL | Completed | Met primary |
| Phase 21 trial | ||||||
| Phase 2 | NCT07277660 | Dec 2025 → May 2027 expected | atopic eczema | UCB Biopharma SRL | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-09-18 | UCB Pharma | Results UCB announces successful first-in-patient trial for galvokimig in moderate-to-severe atopic dermatitis at EADV ucb.com ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-09-18 | UCB Pharma | UCB announces successful first-in-patient trial for galvokimig in moderate-to-severe atopic dermatitis at EADV ucb.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Galvokimig | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07277660 ↗ |
| Known as | UCB9741 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06315335 ↗ |
| Modality | Monoclonal antibody | — CHEMBL5314834 ↗ |
| Route | Intravenous | “intravenous infusion” NCT04643457 ↗ |